Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Alborz Rahmani, Guglielmo Dini, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Alfredo Montecucco, Luca Pellegrini, Alessia Manca, Alexander Domnich, Angela Battistini, Bruno Kusznir Vitturi, Sonia Zacconi, Nicoletta Debarbieri, Giancarlo Icardi, Paolo Durando
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
COVID-19
mRNA vaccine
mass vaccination campaign
occupational health
healthcare workers
reactogenicity
Medicine
R
Accès en ligne:https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/35a8cf0c45474c259c9b93047a78a45f

Documents similaires